[Federal Register Volume 71, Number 15 (Tuesday, January 24, 2006)]
[Notices]
[Pages 3856-3858]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E6-764]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 2006N-0021]


Agency Information Collection Activities; Proposed Collection; 
Comment Request; Request for Samples and Protocols

AGENCY:  Food and Drug Administration, HHS.

ACTION:  Notice.

-----------------------------------------------------------------------

SUMMARY:  The Food and Drug Administration (FDA) is announcing an 
opportunity for public comment on the proposed collection of certain 
information by the agency. Under the Paperwork Reduction Act of 1995 
(the PRA), Federal agencies are required to publish notice in the 
Federal Register concerning each proposed collection of information, 
including each proposed extension of an existing collection of 
information, and to allow 60 days for public comment in response to the 
notice. This notice solicits comments on the information collection 
requirements relating to the regulations which state that protocols for 
samples of biological products must be submitted to the agency.

DATES:  Submit written or electronic comments on the collection of 
information by March 27, 2006.

ADDRESSES:  Submit electronic comments on the collection of information 
to: http://www.fda.gov/dockets/ecomments. Submit written comments on 
the collection of information to the Division of Dockets Management 
(HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, 
Rockville, MD 20852. All comments should be identified with the docket 
number found in brackets in the heading of this document.

FOR FURTHER INFORMATION CONTACT:  Jonna Capezzuto, Office of Management 
Programs (HFA-250), Food and Drug Administration, 5600 Fishers Lane, 
Rockville, MD 20857, 301-827-4659.

SUPPLEMENTARY INFORMATION: Under the PRA (44 U.S.C. 3501-3520), Federal 
agencies must obtain approval from the Office of Management and Budget 
(OMB) for each collection of information they conduct or sponsor. 
``Collection of information'' is defined in 44 U.S.C. 3502(3) and 5 CFR 
1320.3(c) and includes agency requests or requirements that members of 
the public submit reports, keep records, or provide information to a 
third party. Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A)) 
requires Federal agencies to provide a 60-day notice in the Federal 
Register concerning each proposed collection of information, including 
each proposed extension of an existing collection of information, 
before submitting the collection to OMB for approval. To comply with 
this requirement, FDA is publishing notice of the proposed collection 
of information set forth in this document.
    With respect to the following collection of information, FDA 
invites comments on these topics: (1) Whether the proposed collection 
of information is necessary for the proper performance of FDA's 
functions, including whether the information will have practical 
utility; (2) the accuracy of FDA's estimate of the burden of the 
proposed collection of information, including the validity of the 
methodology and assumptions used; (3) ways to enhance the quality, 
utility, and clarity of the information to be collected; and (4) ways 
to minimize the burden of the collection of information on respondents, 
including through the use of automated collection techniques, when 
appropriate, and other forms of information technology.

Request for Samples and Protocols (OMB Control Number 0910-0206)--
Extension)

    Under section 351 of the Public Health Service Act (42 U.S.C. 262), 
FDA has the responsibility to issue regulations that prescribe 
standards designed to ensure the safety, purity, and potency of 
biological products and to ensure that the biologics licenses for such 
products are only issued when a product meets the prescribed standards. 
Under Sec.  610.2 (21 CFR 610.2), FDA may at any time require 
manufacturers of licensed biological products to submit to FDA samples 
of any lot along with the protocols showing the results of applicable 
tests prior to marketing the lot of the product. In addition to Sec.  
610.2, there are other regulations that require the submission of 
samples and protocols

[[Page 3857]]

for specific licensed biological products: Sec. Sec.  660.6 (21 CFR 
660.6) (Antibody to Hepatitis B Surface Antigen), 660.36 (21 CFR 
660.36) (Reagent Red Blood Cells), and 660.46 (21 CFR 660.46) 
(Hepatitis B Surface Antigen).
    Section 660.6(a) provides requirements for the frequency of 
submission of samples from each lot of Antibody to Hepatitis B Surface 
Antigen product, and Sec.  660.6(b) provides the requirements for the 
submission of a protocol containing specific information along with 
each required sample. For Sec.  660.6 products subject to official 
release by FDA, one sample from each filling of each lot is required to 
be submitted along with a protocol consisting of a summary of the 
history or manufacture of the product, including all results of each 
test for which test results are requested by the Center for Biologics 
Evaluation and Research (CBER). After official release is no longer 
required, one sample along with a protocol is required to be submitted 
at an interval of 90 days. In addition, samples, which must be 
accompanied by a protocol, may at any time be required to be submitted 
to FDA if continued evaluation is deemed necessary.
    Section 660.36(a) requires, after each routine establishment 
inspection by FDA, the submission of samples from a lot of final 
Reagent Red Blood Cell product along with a protocol containing 
specific information. Section 660.36(a)(2) requires that a protocol 
contain information including, but not limited to, manufacturing 
records, test records, and test results. Section 660.36 (b) requires a 
copy of the antigenic constitution matrix specifying the antigens 
present or absent to be submitted to FDA at the time of initial 
distribution of each lot.
    Section 660.46(a) provides requirements for the frequency of 
submission of samples from each lot of Hepatitis B Surface Antigen 
product, and Sec.  660.46(b) provides the requirements for the 
submission of a protocol containing specific information along with 
each required sample. For Sec.  660.46 products subject to official 
release by FDA, one sample from each filling of each lot is required to 
be submitted along with a protocol consisting of a summary of the 
history or manufacture of the product, including all results of each 
test for which test results are requested by CBER. After notification 
of official release is received, one sample along with a protocol is 
required to be submitted at an interval of 90 days. In addition, 
samples, which must be accompanied by a protocol, may at any time be 
required to be submitted to FDA if continued evaluation is deemed 
necessary.
    Samples and protocols are required by FDA to help ensure the 
safety, purity, or potency of the product because of the potential lot-
to-lot variability of a product produced from living organisms. In 
cases of certain biological products (e.g., Albumin, Plasma Protein 
Fraction, and specified biotechnology and specified synthetic 
biological products) that are known to have lot-to-lot consistency, 
official lot release is not normally required. However, submissions of 
samples and protocols of these products may still be required for 
surveillance, licensing, and export purposes, or in the event that FDA 
obtains information that the manufacturing process may not result in 
consistent quality of the product.
    The following burden estimate is for the protocols that are 
required to be submitted with each sample. The collection of samples is 
not a collection of information under 5 CFR 1320.3(h)(2). Respondents 
to the collection of information under Sec.  610.2 are manufacturers of 
licensed biological products. Respondents to the collection of 
information under Sec. Sec.  660.6(b), 660.36(a)(2) and (b), and 
660.46(b) are manufacturers of the specific products referenced 
previously in this document. The estimated number of respondents for 
each regulation is based on the annual number of manufacturers that 
submitted samples and protocols for biological products including 
submissions for lot release, surveillance, licensing, or export. Based 
on information obtained from FDA's database system, approximately 70 
manufacturers submitted samples and protocols in fiscal year (FY) 2005, 
under the regulations cited previously in this document. FDA estimates 
that 65 manufacturers submitted protocols under Sec.  610.2, and 4 
manufacturers submitted protocols under the regulations (Sec. Sec.  
660.6 and 660.46) for the other specific products. FDA received no 
submissions under Sec.  660.36, however FDA is using the estimate of 
one protocol submission in the event one is submitted in the future.
    The estimated total annual responses are based on FDA's final 
actions completed in FY 2005, which totaled 4,930, for the various 
submission requirements of samples and protocols for the licensed 
biological products. The rate of final actions is not expected to 
change significantly in the next few years. The hours per response are 
based on information provided by industry. The burden estimates 
provided by industry ranged from 1 to 5.5 hours. Under Sec.  610.2, the 
hours per response are based on the average of these estimates and 
rounded to 3 hours. Under the remaining regulations, the hours per 
response are based on the higher end of the estimate (rounded to 5 or 6 
hours) since more information is generally required to be submitted in 
the protocol than under Sec.  610.2.
    FDA estimates the burden of this collection of information as 
follows:

--------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                       Annual Frequency
                21 CFR Section                   No. of Respondents      per Response    Total Annual Responses   Hours per Response      Total Hours
--------------------------------------------------------------------------------------------------------------------------------------------------------
610.2                                                          65                 74.1                 4,816                     3             14,448
--------------------------------------------------------------------------------------------------------------------------------------------------------
660.6(b)                                                        3                 26                      78                     5                390
--------------------------------------------------------------------------------------------------------------------------------------------------------
660.36(a)(2) and (b)                                            1                  1                       1                     6                  6
--------------------------------------------------------------------------------------------------------------------------------------------------------
660.46(b)                                                       1                 35                      35                     5                175
--------------------------------------------------------------------------------------------------------------------------------------------------------
Total                                                          70     .................                4,930     ....................          15,019
--------------------------------------------------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of information.



[[Page 3858]]

    Dated: January 13, 2006.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. E6-764 Filed 1-23-06; 8:45 am]
BILLING CODE 4160-01-S